Key terms
About ALT
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ALT news
Apr 03
8:11am ET
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Terns Pharmaceuticals (TERN) and Altimmune (ALT)
Apr 01
12:15pm ET
Altimmune’s Pemvidutide Shows Promise for Obesity Treatment, Justifying Buy Rating
Apr 01
12:00pm ET
Altimmune price target lowered to $12 from $15 at H.C. Wainwright
Mar 28
9:05am ET
Altimmune has ‘ideal lifestyle anti-obesity drug,’ says B. Riley
Mar 28
8:00am ET
Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Altimmune (ALT)
Mar 28
7:30am ET
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)
Mar 27
5:25pm ET
Buy Rating Affirmed for Altimmune as Pemvidutide Shows Promising Weight Loss and Lean Mass Preservation
Mar 27
3:40pm ET
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Altimmune (ALT)
Mar 27
3:35pm ET
Piper continues to be bullish on Altimmune
Mar 27
9:41am ET
Unusually active option classes on open March 27th
Mar 27
7:09am ET
Altimmune reports Q4 EPS (54c), consensus (43c)
Mar 25
8:00am ET
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
Mar 05
9:39am ET
Altimmune Stock (NASDAQ:ALT) Rides Volatility Wave Despite Promising Pipeline
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 29
10:57am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 28
11:59am ET
Biotech Alert: Searches spiking for these stocks today
Feb 27
11:25am ET
Altimmune call volume above normal and directionally bullish
Feb 26
2:45pm ET
Altimmune’s Pemvidutide Poised for Market Success: A Buy Rating with a $25 Price Target
Feb 26
10:16am ET
Madrigal Pharmaceuticals downgraded to Sell at B. Riley after competitor data
Feb 26
9:40am ET
Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)
Feb 26
9:40am ET
Unusually active option classes on open February 26th
Feb 15
8:55am ET
Altimmune (ALT) Gets a Buy from Piper Sandler
Feb 13
10:35pm ET
Buy Rating for Altimmune Backed by Pemvidutide’s Promise and Market Potential
Feb 13
2:44pm ET
Altimmune short report includes ‘factual inconsistencies,’ says B. Riley
Feb 09
2:25pm ET
Altimmune call volume above normal and directionally bullish
Feb 06
3:15pm ET
Altimmune’s Pemvidutide Shows Promising Outlook in NASH and Obesity Markets: A Strong Buy Rating
Jan 24
4:43am ET
Altimmune reinstated with a Neutral at Goldman Sachs
Jan 24
2:38am ET
Maintaining Hold on Altimmune: Balancing Phase 2 Promise with Strategic Partnership Needs
Jan 22
2:10pm ET
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), 10x Genomics (TXG) and Altimmune (ALT)
Jan 12
8:30am ET
Analysts Conflicted on These Healthcare Names: Legend Biotech (LEGN), Altimmune (ALT) and Apellis Pharmaceuticals (APLS)
No recent press releases are available for ALT
ALT Financials
Key terms
Ad Feedback
ALT Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ALT Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
